Vyome (HIND) Q1 2026 earnings summary

Executive summary

• Completed a reverse merger with Reshape Lifesciences in August 2025, resulting in a Nasdaq listing and a new focus on immunoinflammatory and rare disease therapeutics.

• Achieved disciplined execution and progress, advancing VT-1953 toward pivotal development and expanding the pipeline with VT-1908 and in-licensed JAK inhibitor assets.

• Signed an exclusive global license for preclinical JAK inhibitor assets from Impetis Biosciences, targeting a ~$57 billion global market, with only a 1.5% royalty on future net sales and no upfront or milestone payments.

• Maintained a clean capital structure with no debt, preferred stock, toxic financing, or warrant overhang; all convertible notes and preferred stock were converted to common stock at the merger.

• Commercialized antifungal products in India through Sun Pharma, with legacy licensing agreements generating minor royalties.

Financial highlights

• Cash and cash equivalents increased to $8.8 million as of March 31, 2026, up from $5 million at December 31, 2025, due to ATM and premium-priced equity sales.

• Total assets reached $10.2 million; stockholders' equity was $8 million at quarter-end.

• Q1 2026 revenues were $31,591, down from $198,581 in Q1 2025, reflecting the wind-down of legacy Sun Pharma agreements.

• Operating expenses for Q1 2026 were $1.15 million, with R&D at $666,405 and SG&A at $478,000.

• Net loss attributable to common shareholders was $963,000, or $0.15 per share, with a gross margin of 53%.

Outlook and guidance

• Focus remains on advancing VT-1953 toward pivotal-stage readiness and regulatory engagement, with continued disciplined capital allocation.

• Management expects continued operating losses and increased R&D spending as clinical programs advance.

• Current cash is expected to fund operations for at least 15 months, including the initiation of a pivotal trial for VT-1953, but not through completion; additional capital will be required.

• Exploring non-dilutive pathways for JAK inhibitor assets, with updates expected in coming quarters.